Treatment of symptomatic diabetic peripheral neuropathy with the protein kinase C beta-inhibitor ruboxistaurin mesylate during a 1-year, randomized, placebo-controlled, double-blind clinical trial Article

authors

publication date

  • August 1, 2005

webpage

published in

keywords

  • adverse events
  • clinical trials
  • diabetic peripheral neuropathy
  • phase II
  • ruboxistaurin

start page

  • 1164

end page

  • 1180

volume

  • 27

issue

  • 8